The rise of GLP-1 drugs for weight loss has been meteoric, with many Americans turning to telehealth companies for access. But this trend has raised serious safety concerns, as evidenced by the case of Leslie Gammon, a North Carolina woman who suffered a GLP-1 overdose after using a compounded drug from a telehealth company. This incident highlights the potential risks associated with self-prescribing and the lack of oversight in some telehealth settings.
The Growing Trend of GLP-1 Use
GLP-1 drugs, which mimic the effects of the hormone glucagon-like peptide-1, have become increasingly popular for weight loss. According to Gallup, 11% of U.S. adults now report taking GLP-1s for this purpose, a significant increase from previous years. This surge in popularity has been fueled by the convenience and accessibility of telehealth services, which allow patients to obtain these medications without in-person appointments.
The Dangers of Overdose
Gammon's experience is not an isolated incident. The National Poison Data System reports a staggering 1,500% increase in calls related to GLP-1 overdose or side effects between 2019 and 2025, with nearly 23,000 cases. This data suggests that the lack of proper supervision and oversight in some telehealth settings is leading to serious health consequences for patients.
Dr. Fatima Syed, an associate professor of medicine at Duke University, emphasizes the importance of clinical oversight in managing weight and other health conditions. She argues that a simple click or text message is not sufficient for ensuring patient safety, especially when it comes to medications like GLP-1, which can be dangerous if not used properly.
The Role of Telehealth Companies
Telehealth companies have a responsibility to ensure patient safety and provide adequate follow-up care. However, the current system often falls short. Gammon's experience with two different telehealth companies highlights the challenges of relying solely on email communication for medication management. The lack of direct interaction with a medical professional can lead to confusion and potential harm.
Brand-Name vs. Compounded Drugs
It's crucial for patients to understand the difference between brand-name GLP-1 drugs, such as Wegovy and Zepbound, which are FDA-approved, and compounded GLP-1 drugs, which are not. Syed notes that compounded drugs may be cheaper, but they are not subject to the same safety standards as brand-name medications. This can lead to confusion and potential misuse, as evidenced by reports of patients accidentally taking 10 times the recommended dose.
The Need for Stronger Oversight
The Alliance for Compounded Pharmacies has called for stronger oversight and transparency in the compounding process, especially in light of the GLP-1 boom. They argue that mass-produced copies of drugs operating in regulatory gray areas pose significant risks to patient safety. Both Novo Nordisk and Eli Lilly have expressed concerns about the safety of compounded versions of their GLP-1 medications, warning patients about the potential dangers of knockoff products.
Conclusion
The case of Leslie Gammon serves as a stark reminder of the potential risks associated with GLP-1 drugs and the importance of proper oversight in telehealth settings. As the popularity of these medications continues to grow, it is crucial for patients to choose reputable telehealth companies that provide clear communication and easy access to medical professionals. Only then can we ensure that the benefits of GLP-1 drugs are realized without compromising patient safety.
